AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study NCT03846154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive family intervention including individual sessions of FORNET
Description: 1. A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~2. Access to schools and school material~3. Family visits~4. Their parents received training regarding agriculture and microcredit projects, and financial assistance~5. FORNET if affected by trauma-related symptoms, and/or acting aggressive~6. If needed medical assistance /.) If needed, legal assistance
Study NCT03686228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PB-MNC therapy
Description: The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
Study NCT03686228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No-PB-MNC therapy
Description: Patients will receive ASA 81 mg once daily and wound care and pain killer drug
Study NCT01319656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support, management, educational, counselling, follow-up
Description: The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
Study NCT01204320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated Balloon
Description: POBA
Study NCT01204320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting Stent
Description: Stenting
Study NCT01079676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (Eurofarma)
Description: Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
Study NCT01079676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim (Granulokine, Amgen)
Description: Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
Study NCT03867812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOBAR
Description: SOBAR is a high protein nutrition bar optimized to delay gastric emptying
Study NCT03867812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control food
Description: Chexmix (General Mills Inc.), Honey Nut Flavor
Study NCT03867812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full meal
Description: Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
Study NCT01134445 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Proxima™ Hip
Description: A short, anatomic, cementless femoral component for use in total hip arthroplasty
Study NCT06194370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training by BOPPPS Teaching Model
Description: Training by BOPPPS Teaching Model
Study NCT06194370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training Regularly
Description: Training Regularly
Study NCT01209585 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Subjects will have visits on Days 1, 30 and 120.
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT02007434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Compress
Description: A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
Study NCT02007434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold Compress
Description: A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine / Epinephrine
Description: Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine / Epinephrine
Description: Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine 10 mg orally from Day -7 until Day 7
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: Loratadine 10 mg orally from Day -7 until Day 7
Study NCT01209585 — intervention group
Intervention type: OTHER
Intervention: Synovial fluid aspiration
Description: Subjects will have visits on Days 1, 30, and 120.
Study NCT01209585 — intervention group
Intervention type: OTHER
Intervention: Synovial tissue sample
Description: Subjects will have visits on Days 1, 30, and 120.
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
Study NCT03964038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gilteritinib
Description: oral
Study NCT03964038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib mini tablet
Description: oral
Study NCT02007434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
Study NCT02007434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Chin Strap
Description: A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
Study NCT02007434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Compression Chin Strap
Description: A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
Study NCT00855062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: 100 mg capsule every 12 hours by mouth
Study NCT00855062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: minocycline placebo capsule
Description: 1 capsule every 12 hours by mouth
Study NCT03002610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pls
Description: Text format with simple explanation of the survey topic main findings and is intended for lay audience.
Study NCT03002610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographics
Description: Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
Study NCT03002610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific abstract
Description: Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
Study NCT04367857 — intervention group
Intervention type: OTHER
Intervention: COVID-19 Serology
Description: Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
Study NCT04367857 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health Care Worker Survey
Description: The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
Study NCT02694705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
Study NCT02694705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bag-Valve-Mask (BVM)
Description: Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
Study NCT02694705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-rebreather Mask (NRM)
Description: Preoxygenation provided by NRM, oxygen flow rate 15 l/min
Study NCT01429636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Relaxation (MR)
Description: The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
Study NCT01429636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Description: Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
Study NCT01355458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 gel
Description: applied topically once daily
Study NCT01355458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: applied topically once daily
Study NCT02708979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: University exam-period
Description: This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
Study NCT02708979 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: University non-exam-period
Description: This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
Study NCT03788538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
Study NCT00530062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol-HFA-MDI
Description: Inhalation Aerosols, 90 mcg, 1 dose per treatment period
Study NCT00530062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol-HFA-BAI
Description: Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
Study NCT01822587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol, 40 mg
Study NCT01822587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol, 80 mg
Study NCT01822587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02454192 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHAMPS
Study NCT03050502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube drain
Description: This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
Study NCT03050502 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectant management
Description: This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
Study NCT01655862 — intervention group
Intervention type: BIOLOGICAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
Study NCT02253355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Study NCT02253355 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study NCT03431402 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyperbaric oxygen
Description: - HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
Study NCT03879746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: drug will be used in treatment of premature ejaculation
Study NCT03879746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine Hydrochloride
Description: drug will be used in treatment of premature ejaculation
Study NCT03879746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets without active substance will be given to patients suffering from premature ejaculation
Study NCT04225533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP16
Description: All patients will receive a single dose of SP16
Study NCT00708916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-10004
Description: 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
Study NCT03595332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summer activity program
Description: Children receive a summer scorecard to facilitate access to local facilities for exercise.
Study NCT00816465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hoodia gordonii
Description: PO administration of 1 Tab Hoodia gordoni extract per day.
Study NCT00816465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO Placebo pill
Study NCT04110002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injury Prevention Program
Study NCT04209478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
Study NCT04563468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength inspiratory muscle training
Description: Two training sessions per day consisting of 30 breaths (against external load of \~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at \~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
Study NCT04563468 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endurance inspiratory muscle training
Description: Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
Study NCT01089374 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Partial breast radiation after lumpectomy
Description: Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
Study NCT02657317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FORT-A
Description: FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
Study NCT02657317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VA Treatment as Usual
Description: VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
Study NCT03786861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal WFG group
Description: TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
Study NCT03786861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aberration free group
Description: TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV
Description: 10 mg tablet administered orally once daily
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF placebo
Description: Tablet administered orally once daily
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV placebo
Description: Tablet administered orally once daily
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT00117676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT04710745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.
Description: Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
Study NCT04710745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: ECHO parameters:~* E/e´~* Mean e' septal and lateral wall~* LA volume (Biplane Area-Length Method)~* Left atrial volume index~* Diameter of left atrium in PLAX~* Severe aortic stenosis~* Severe mitral regurgitation~* Severe tricuspid regurgitation~* Left ventricular end-diastolic diameter~* Interventricular septum~* Posterior wall~* LV Mass~* Left ventricular mass index
Study NCT04710745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG Holter monitor
Description: Patient receives an ECG Holter for a 7-day monitoring.
Study NCT04710745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized Mini-Mental Status Exam (SMMSE)
Description: A screening test for evaluating cognitive performance of patients done in the clinician's office.
Study NCT02216266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physostigmine
Study NCT02216266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride solution